Qi X, Li F, Wu Y, Cheng C, Han P, Wang J, et al. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity. Nat Commun. 2019;10:2141 pubmed publisher

Giardino Torchia M, Munitic I, Castro E, Herz J, McGavern D, Ashwell J. c-IAP ubiquitin protein ligase activity is required for 4-1BB signaling and CD8(+) memory T-cell survival. Eur J Immunol. 2015;45:2672-82 pubmed publisher

Kobayashi T, Doff B, Rearden R, Leggatt G, Mattarollo S. NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma. Oncoimmunology. 2015;4:e990793 pubmed

Guillerey C, Ferrari de Andrade L, Vuckovic S, Miles K, Ngiow S, Yong M, et al. Immunosurveillance and therapy of multiple myeloma are CD226 dependent. J Clin Invest. 2015;125:2077-89 pubmed publisher

Tewalt E, Cohen J, Rouhani S, Guidi C, Qiao H, Fahl S, et al. Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood. 2012;120:4772-82 pubmed publisher

Verbrugge I, Hagekyriakou J, Sharp L, Galli M, West A, McLaughlin N, et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 2012;72:3163-74 pubmed publisher

Vezys V, Penaloza MacMaster P, Barber D, Ha S, Konieczny B, Freeman G, et al. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. J Immunol. 2011;187:1634-42 pubmed publisher